VBI Vaccines Inc. (VBIVQ)
| Market Cap | 14.34K |
| Revenue (ttm) | 9.41M |
| Net Income (ttm) | -83.99M |
| Shares Out | 28.68M |
| EPS (ttm) | -4.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 723 |
| Open | 0.0005 |
| Previous Close | 0.0005 |
| Day's Range | 0.0005 - 0.0005 |
| 52-Week Range | 0.0005 - 1.3500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 14, 2024 |
About VBI Vaccines
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops ... [Read more]
Financial Performance
In 2023, VBI Vaccines's revenue was $8.68 million, an increase of 702.40% compared to the previous year's $1.08 million. Losses were -$93.84 million, -17.18% less than in 2022.
Financial StatementsNews
Dow Jumps Over 300 Points; US Trade Gap Narrows In June
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.88% to 39,042.26 while the NASDAQ ro...